- Home
- ADIL vs AEON Comparison
ADIL vs AEON Comparison
Compare ADIL & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | AEON |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 13.0M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ADIL | AEON |
|---|---|---|
| Price | $4.22 | $0.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $8.33 | $1.82 |
| AVG Volume (30 Days) | 34.3K | ★ 1.2M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.18 |
| 52 Week High | $9.53 | $1.45 |
Technical Indicators
Market Signals| Indicator | ADIL | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 42.31 |
| Support Level | $3.80 | $0.23 |
| Resistance Level | $4.94 | $0.33 |
| Average True Range (ATR) | 0.37 | 0.03 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 77.33 | 12.23 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.